Table 3.
Adverse events during follow-up in AS patients switched to BI versus those continuing RI.
| Adverse Events * n (%) | Switched Group (BI) | Continued Group (RI) | p-Value |
|---|---|---|---|
| Upper respiratory tract infections | 3 (6.6) | 2 (4.6) | NS |
| Urinary tract infections | 2 (4.4) | 2 (4.6) | NS |
| Skin infections | 2 (2.2) | 1 (2.3) | NS |
| Increased liver enzymes | 2 (4.4) | 2 (4.6) | NS |
| Diarrhea | 1 (2.2) | 2 (4.6) | NS |
| Viral infections | 2 (4.4) | 1 (2.3) | NS |
| Headache | 1 (2.2) | 0 (0) | NS |
| Hypertension | 1 (2.2) | 1 (2.3) | NS |
*, not requiring discontinuation; BI, Biosimilar Infliximab; RI, Reference Infliximab; n, number of patients; NS, Non-statistical.